• Dose-Dependent PDCoV Infection: Immune Activation and Molecu

  2026-07-14

  This study reveals how the infectious dose of porcine deltacoronavirus (PDCoV) determines the scale and nature of host immune responses, with high doses inducing excessive inflammation and low doses primarily activating antiviral pathways. These mechanistic findings clarify the role of STAT1 and its downstream interferon-stimulated genes (ISG15, MX2) in controlling PDCoV, informing targeted approaches for immunomodulation in swine disease models.

• Targeting ERα DBD-LBD Interface: Mitoxantrone's Novel Mechan

  2026-07-14

  Wang et al. identify mitoxantrone as an allosteric inhibitor of estrogen receptor alpha (ERα), disrupting its function by binding to the DBD-LBD interface and inducing rapid proteasomal degradation. This mechanistic advance overcomes resistance mutations in luminal breast cancer and establishes a new paradigm for nuclear receptor targeting.

• Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Angi

  2026-07-13

  This study establishes anlotinib hydrochloride as a highly potent and selective inhibitor of VEGFR2, demonstrating superior anti-angiogenic activity and tumor growth suppression in preclinical models. The findings clarify mechanistic and selectivity advantages over earlier tyrosine kinase inhibitors and inform experimental design for cancer and angiogenesis research.

• MDM1 Overexpression Enhances Apoptosis and Therapy Response

  2026-07-13

  This study uncovers how MDM1 overexpression in colorectal cancer (CRC) promotes p53 expression and apoptosis, leading to improved chemoradiotherapy sensitivity. The findings establish MDM1 as both a mechanistic biomarker and a potential target for overcoming therapeutic resistance in CRC.

• SOAT1 Inhibition Restores Lipophagy in PHMG-Induced Lung Fib

  2026-07-12

  This study identifies sterol O-acyltransferase 1 (SOAT1) as a key mediator of foam cell formation and lipid dysregulation in PHMG-induced pulmonary fibrosis, showing that SOAT1 inhibition restores macrophage lipophagy and reduces fibrotic progression. These findings provide a mechanistic basis for targeting SOAT1 in the treatment of environmentally triggered lung fibrosis.

• 11β-HSD1 Inhibition Reduces Liver Fibrosis via Notch and NK

  2026-07-10

  A recent study demonstrates that selective inhibition of 11β-HSD1 significantly reduces liver fibrosis by suppressing the Notch signaling pathway and enhancing natural killer (NK) cell-mediated clearance of hepatic stellate cells. These findings provide mechanistic insight into immunometabolic regulation in metabolic dysfunction-associated steatotic liver disease (MASLD) and highlight new anti-fibrotic therapeutic targets.

• GRA12: A Broad-Spectrum Virulence Factor in Toxoplasma gondi

  2026-07-09

  This study systematically identified GRA12 as a conserved, secreted virulence factor critical for Toxoplasma gondii survival across diverse parasite strains and mouse subspecies. The findings deepen our mechanistic understanding of host-pathogen interactions and provide a refined platform for dissecting immune evasion in apicomplexan parasites.

• Bufuralol Hydrochloride in β-Adrenergic Modulation Workflows

  2026-07-09

  Bufuralol hydrochloride empowers researchers to interrogate human β-adrenergic signaling with unprecedented fidelity using advanced hiPSC-derived intestinal organoid systems. Its partial agonist activity and robust membrane-stabilizing effects make it uniquely suited for translational cardiovascular pharmacology and drug metabolism studies.

• Annexin V: Strategic Advances in Apoptosis and Immune Tolera

  2026-07-08

  This thought-leadership article, authored by APExBIO’s scientific marketing team, explores the evolving landscape of Annexin V applications in cell death and immune tolerance research. Blending mechanistic insights with actionable guidance for translational investigators, we connect the latest mechanistic findings—such as miR-519d-3p’s role in preeclampsia—with the strategic deployment of recombinant Annexin V as a precision tool for apoptosis assay design and immune modulation studies. We review the competitive landscape, protocol best practices, and emerging translational frontiers, providing mature, evidence-driven recommendations for researchers seeking to bridge fundamental discoveries with clinical impact.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Advance

  2026-07-08

  PYR-41, the selective inhibitor of Ubiquitin-Activating Enzyme E1 from APExBIO, empowers researchers to dissect protein degradation and immune signaling with unprecedented precision. This guide delivers practical protocols, troubleshooting strategies, and actionable insights for leveraging PYR-41 in translational inflammation and viral immunity models.

• Hydrocortisone in Inflammation and Stemness Models: Protocol

  2026-07-07

  Hydrocortisone from APExBIO empowers researchers to dissect glucocorticoid hormone effects in inflammation, stress response, and cancer stemness models with precision. This article delivers workflow upgrades, protocol optimizations, and troubleshooting intelligence — especially for multidimensional tumor microenvironment studies.

• A-1210477: Optimizing MCL-1 Inhibitor Workflows in Cancer Re

  2026-07-07

  A-1210477, a potent MCL-1 inhibitor, allows researchers to dissect MCL-1-dependent apoptosis with unmatched specificity. This article delivers actionable workflow upgrades, troubleshooting advice, and comparative insights to boost reproducibility and mechanistic clarity in cancer cell survival studies.

• Bufuralol Hydrochloride in iPSC Organoids for Cardiovascular

  2026-07-06

  Bufuralol hydrochloride unlocks more human-relevant, reproducible pharmacokinetic and β-adrenergic modulation studies by integrating seamlessly into iPSC-derived intestinal organoid platforms. This article delivers practical, protocol-level guidance and troubleshooting strategies that set your cardiovascular pharmacology assays apart.

• Lysozyme–Amikacin Complex Formation: Insights into Antibioti

  2026-07-06

  This article examines recent findings on the interaction between lysozyme and amikacin, highlighting how complex formation preserves protein structure but abolishes enzymatic activity. The study integrates advanced spectroscopy and molecular docking, offering new perspectives for antibiotic mechanism and resistance research.

• Firefly Luciferase mRNA (ARCA, 5-moUTP): Stability, Delivery

  2026-07-05

  Explore how Firefly Luciferase mRNA (ARCA, 5-moUTP) advances bioluminescent assays through enhanced molecular stability and translational efficiency. This article uniquely bridges molecular design with real-world delivery and storage innovations, providing fresh insights for robust gene expression and in vivo imaging workflows.

16292 records 1/1087 page Next 12345 下5页 Last page